![]() | ![]() |
Formats:
|
||||||||||||
Copyright © 2007, European Molecular Biology Organization Scientific Report Cyclic AMP signalling in Dictyostelium: G-proteins activate separate Ras pathways using specific RasGEFs 1Department of Microbiology and Immunology, University of British Columbia, 3540-2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada 2Department of Molecular Cell Biology, University of Groningen, Kerklaan 30, 9751NN Haren, The Netherlands 3Department of Physiological Chemistry and Centre of Biomedical Genetics, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands 4School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK aTel: +604 822 0997; Fax: +604 822 6041; E-mail: gerwee/at/interchange.ubc.ca Received November 27, 2006; Revised February 6, 2007; Accepted February 6, 2007. This article has been cited by other articles in PMC.Abstract In general, mammalian Ras guanine nucleotide exchange factors (RasGEFs) show little substrate specificity, although they are often thought to regulate specific pathways. Here, we provide in vitro and in vivo evidence that two RasGEFs can each act on specific Ras proteins. During Dictyostelium development, RasC and RasG are activated in response to cyclic AMP, with each regulating different downstream functions: RasG regulates chemotaxis and RasC is responsible for adenylyl cyclase activation. RasC activation was abolished in a gefA− mutant, whereas RasG activation was normal in this strain, indicating that RasGEFA activates RasC but not RasG. Conversely, RasC activation was normal in a gefR− mutant, whereas RasG activation was greatly reduced, indicating that RasGEFR activates RasG. These results were confirmed by the finding that RasGEFA and RasGEFR specifically released GDP from RasC and RasG, respectively, in vitro. This RasGEF target specificity provides a mechanism for one upstream signal to regulate two downstream processes using independent pathways. Keywords: Ras, RasGEF, signal transduction, GDP release, Dictyostelium Introduction Ras proteins are small, monomeric GTPases that act as crucial regulators of a number of cellular signalling pathways, including those involved in proliferation, differentiation and apoptosis. Ras is inactive when bound to GDP but activated when bound to GTP; the exchange of GDP for GTP is catalysed by a group of proteins called Ras guanine nucleotide exchange factors (RasGEFs). Therefore, RasGEFs are crucial regulatory molecules for all Ras-linked signal-transduction pathways. Inactivation of Ras is catalysed by Ras GTPase-activating proteins (RasGAPs), which stimulate the hydrolysis of GTP by Ras. Ras signalling in mammalian cells is extremely complex, involving 36 Ras subfamily proteins (Wennerberg et al, 2005) and an even greater number of RasGEFs (Quilliam et al, 2002). In addition, mammalian RasGEFs show little specificity for a particular Ras in vitro, making it difficult to define signalling networks. By contrast, the social amoeba Dictyostelium discoideum provides a relatively simple system in which to investigate Ras function in that there are fewer Ras proteins and each Ras protein seems to regulate a unique subset of functions (Lim et al, 2002). There are 25 sequences in the Dictyostelium genome with homology to the RasGEF catalytic domain, but little is known about which of these regulates the individual Ras proteins. Only three RasGEFs have been linked to possible Ras substrates, and in each case the evidence is merely based on phenotypic similarity of ras and gef gene knockout mutants (Lim et al, 2001; King & Insall, 2003; Wilkins et al, 2005). In this report, we provide in vivo and in vitro evidence for highly specific RasGEF–Ras interactions. Results RasGEFA mediates cAMP induced RasC activation In a previous report, we described a Ras-binding domain (RBD) binding assay that allowed the measurement of the level of activated Ras in Dictyostelium cell lysates. This assay uses the RBD of the Schizosaccharomyces pombe Ras effector protein Byr2, which preferentially binds to activated Ras, to separate Ras-GTP from the pool of total cellular Ras. We showed that cyclic AMP (cAMP) induced activation of two Ras proteins: RasC, RasG (Kae et al, 2004). However, it was necessary to overexpress RasC to assay its activation. We have now increased the sensitivity of the assay by modifying the lysis buffer and by using an enhanced chemiluminescent detection system. With this improved assay, it has been possible to measure RasC activation in wild-type Ax3 cells. Both RasC and RasG showed the same rapid and transient activation in response to cAMP, and maximum activation was reached 10 s after stimulation (data not shown), which is consistent with the previous results. Insall et al (1996) identified RasGEFA, formerly known as AleA, as a component involved in G-protein-mediated cAMP signalling events. Strains with a disrupted rasC gene had a phenotype similar to that of the gefA− mutant; therefore it was speculated that RasGEFA might mediate RasC activation (Lim et al, 2001). However, it was not possible to test this idea genetically by the expression of activated RasC in the gefA− strain because such expression had deleterious effects on early development (Lim, 2002). The modifications to the RBD binding assay allowed for an alternative strategy. Six-hour cAMP-pulsed Ax3 and gefA− cells were stimulated with cAMP, and the levels of activated RasC and RasG were measured at various time points after stimulation. No activation of RasC was observed in cells lacking RasGEFA (Fig 1
RasGEFR is required for maximal activation of RasG The availability of other gef gene null strains (Wilkins et al, 2005) provided an opportunity to search for the RasGEF protein responsible for activation of RasG. When pulsed gefR− cells were stimulated with cAMP there was a partial reduction in RasG activation, although there was no effect on RasC activation (Fig 2A
RasGEFA and RasGEFR are highly specific in vitro RasGEFs catalyse the release of GDP from Ras-GDP and this can be measured by using an in vitro fluorescence nucleotide exchange assay. To determine the in vitro activity and substrate specificities of RasGEFA and RasGEFR, the CDC25 domains of RasGEFA (GefACDC25) and RasGEFR (GefRCDC25) were expressed in bacteria as glutathione-S-transferase (GST) fusion proteins, purified and enzymatically cleaved from the GST tag. To provide substrates for these in vitro assays, full-length RasD and RasG, and carboxy-terminal truncations of RasB (1–169; RasC (1–168) and Rap1 (1–169; RasBCT, RasCCT and Rap1CT) were also expressed in bacteria and purified. The C-terminal Ras truncations were used because they are similar to full-length proteins in their physical and biochemical properties (John et al, 1990); however their greater stability facilitated their expression and purification. The Ras proteins were loaded with a fluorescent GDP analogue, mGDP (2′-(or 3′)-O-(N-methylanthraniloyl)-guanosine 5′-diphosphate), incubated in the presence of an excess of GDP and either GefACDC25 or GefRCDC25. Nucleotide release was followed as the decrease of fluorescence with time. To control for the stability and folding of the purified Dictyostelium Ras and Rap proteins, the human RasGEF CDC25 (also known as RasGRF1) and the RapGEF C3G were used as controls (Figs 3
When RasCCT-mGDP was incubated with GefACDC25, there was a significantly enhanced decrease in fluorescence compared with the basal intrinsic decrease in the absence of a GEF indicating that GefACDC25 was able to catalyse GDP release from RasCCT (Fig 3A Discussion The Dictyostelium genome encodes 14 Ras subfamily proteins (Weeks et al, 2005), a number that is considerably greater than that found in yeast and other fungi. In addition, there are more gef genes than ras genes encoded by the Dictyostelium genome (Wilkins et al, 2005), indicating that at least some Ras proteins are activated by more than one RasGEF. Consistent with this idea, of the ten gef gene knockouts that have been described, several have no distinct phenotype (Wilkins et al, 2005). The isolation of a gefA− strain that failed to aggregate was the first indication of a Ras protein being involved in cAMP signalling during Dictyostelium development (Insall et al, 1996). The subsequent isolation of a rasC− null mutant with a similar phenotype indicated the possibility that RasC functioned downstream of RasGEFA (Lim et al, 2001). The pattern of Ras activation in the gefA− mutant provided convincing evidence that RasGEFA is necessary for the activation of RasC in response to cAMP, but not required for RasG activation in response to cAMP (Fig 1 A proteomic study had shown that RasGEFR was the only RasGEF that showed an alteration in phosphorylation in response to the expression of activated RasG, indicating a possible connection (Secko et al, 2004). However, there was no direct evidence to show that RasGEFR mediated RasG activation. The finding of a significant reduction in the magnitude of RasG activation in response to cAMP in a gefR− mutant (Fig 2C In three cases (Figs 1 The findings that RasGEFA is specific for RasC and that RasGEFR is specific for RasG are consistent with the idea that RasC and RasG are involved in different responses generated from the cAMP stimulus: RasC is predominantly involved in the activation of the adenylyl cyclase expressed during aggregation (ACA), whereas RasG predominantly involved in chemotaxis (Bolourani et al, 2006). In chemotaxing cells it has been shown that activated Ras appears at the tip of the pseudopod within 10 s of an applied cAMP stimulus (Sasaki et al, 2004). We believe that the activated Ras detected by Sasaki et al (2004) is RasG because the Raf1–RBD used for the assay has a higher affinity for RasG than RasC (Kae et al, 2004). RasC and RasG each have their own specific RasGEFs. As ACA is localized at the rear of the cell (Kriebel et al, 2003), it is tempting to speculate that RasGEFA is also localized at the rear of the cell where RasC activation would be responsible for ACA activation. A precedent for Ras signalling occurring in two distinct subcellular domains was proposed for T cells, in which Ras is activated at the plasma membrane by SOS1 and at the Golgi membrane by RasGRP1 (Bivona et al, 2003). At present, a reagent that will specifically detect activated RasC in the cell is not available; therefore, it is not possible to determine whether the activation of RasC and RasG have different localizations. The high degree of RasGEF–Ras specificity in Dictyostelium is in contrast to the situation in mammalian cells, in which overlapping specificities are common (Quilliam et al, 2002). For example, SOS1 shows in vitro exchange activity on one group of Ras proteins (H-Ras, K-Ras, N-Ras, M-Ras and R-Ras; Porfiri et al, 1994; Ohba et al, 2000; Nielsen et al, 2001), and RasGRF1 has been shown to activate a second group of Ras proteins (H-Ras, K-Ras, N-Ras, M-Ras, R-Ras1 and R-Ras2; Ohba et al, 2000; Nielsen et al, 2001). Little is known about the structural determinants of Ras that might be involved in conferring RasGEF specificity. Analysis of a SOS1–Ras crystal structure has shown that three regions are involved in the RasGEF–Ras interaction: Switch 1 region (residues 21–40), Switch 2 region (57–75) and helix α3 region (95–111; Boriack-Sjodin et al, 1998). RasC and RasG show a number of differences in the Switch 1 (4 out of 19 residues), Switch 2 (2 out of 19) and helix α3 regions (6 out of 17), providing various possible determinants of specificity. However, RasGEFR is able to activate RasG but not RasD, despite the fact that RasD and RasG are highly related (89% identity). In fact, RasD and RasG have identical Switch 1 and 2 regions and differ by only one residue, at position 111 in the helix α3 region, with most of the differences between these two proteins confined to the C-terminal residues. Therefore, the high degree of identity in the Switch 1 and Switch 2 regions, and even the helix α3 regions, between RasD and RasG indicates that the RasGEFR–RasG specificity might involve other residues. A detailed mutational analysis is required to determine which Ras residues are the important determinants that confer specificity for RasGEFA as opposed to RasGEFR. Methods Cell culture and development. D. discoideum Ax3, gefA−, gefC−, gefD− and gefR− cells were grown in HL5 medium (Watts & Ashworth, 1970) supplemented with 50 μg/ml streptomycin (Sigma, St Louis, MO, USA). To prepare pulsed aggregation competent cells, vegetative cells were washed three times and resuspended at 5 × 106 cells/ml in KK2 (20 mM potassium phosphate (pH 6.1)), shaken at 160 r.p.m. for 1 h and then pulsed with 50 nM cAMP every 6 min. After pulsing for 5 h, cells were collected by centrifugation, washed twice in KK2 and resuspended in KK2 at 5 × 107 cells/ml. RBD-binding assay. The assay was carried out as described previously (Kae et al, 2004), with one modification. The buffer used for cell lysis (2 × RBD-LB buffer) contained 20 mM sodium phosphate (pH 7.2), 2% Triton X-100, 20% glycerol, 300 mM NaCl, 20 mM MgCl2, 2 mM EDTA, 2 mM Na3VO4, 10 mM NaF and two protease-inhibitor tablets (Roche, Basel, Switzerland) per 50 ml of buffer. Six-hour-pulsed aggregation-competent cells were stimulated by the addition of 200 nM cAMP. Aliquots (400 μl) were taken at selected time points and lysed by the addition of an equal volume of ice-cold 2 × RBD-LB and incubated on ice for 5 min. The lysates were cleared by centrifugation at 12,000g for 10 min and protein concentrations were determined by using the DC Protein Assay (Bio-Rad, Hercules, CA, USA). The same mass of protein (800 μg) from each lysate was incubated with 100 μg of purified recombinant GST–RBD bound to glutathione Sepharose beads (GE Healthcare, Baie d'Urfe, Canada) and the mixture was tumbled at 4°C for 1 h. Beads were collected by centrifugation and washed three times in 1 × RBD-LB. A 50 μl portion of 1 × SDS gel loading buffer was added to the pelleted beads and the mixture was boiled for 5 min. Samples were fractionated by SDS–polyacrylamide gel electrophoresis, blotted onto nitrocellulose, blocked with non-fat milk and probed with antibodies specific for RasC or RasG. The bound antibody was detected by using an ECL-Plus (GE Healthcare) reaction. Expression and purification of recombinant proteins. The catalytic domain of RasGEFA (aa 182–605) was amplified from complementary DNA using the primers 5′-GAGGATCCAAAATGACCACAGAATACGATA-3′ and 5′-GAGCGGCCGCTTAAAGAACATCAGATCTTTGA GC-3′. The catalytic domain of RasGEFR (aa 1,298—1,676) was amplified from cDNA using the primers 5′-GAGGATCCATGGGTACATTAAATAAATTAATT TC-3′ and 5′-GAGCGGCCGCTTATCTTGGTTCACGAATTAAA GAG-3′. The resulting fragments were cloned into pGEX 4T-3 (Stratagene, La Jolla, CA, USA). The catalytic domain of CDC25 and the Ras proteins have been described previously (Lenzen et al, 1998; Kortholt et al, 2006). All of the recombinant proteins were expressed in Escherichia coli BL21 (DE3) codonplus-RIL (Stratagene) and purified as described by Kae et al (2004) and Kortholt et al (2006). In vitro guanine nucleotide release assays. GEF-induced nucleotide release was measured as described previously (Lenzen et al, 1995). Briefly, the Ras proteins were loaded with the fluorescent GDP analogue mGDP (Jena Bioscience, Jena, Germany) by incubation in the presence of 10 mM EDTA and a 20-fold excess of mGDP for 2 h at 25°C. The mGDP-loaded Ras proteins were incubated at 25°C in assay buffer (50 mM Tris–HCl (pH 7.5), 5 mM MgCl2, 50 mM NaCl and 5 mM DTE) containing a 200-fold excess of unlabelled GDP, with 1 μM RasGEF protein. Nucleotide exchange was measured in real time as decay in fluorescence using a Spex1 spectrofluorometer (Spex Industries, Meutchen, NJ, USA), with excitation and emission wavelengths of 366 and 450 nm, respectively. Acknowledgments G.W. was supported by a grant from Canadian Institutes of Health Research (CIHR) of Canada. R.H.I. was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grant G17939. Work by A.K. and P.V.H. was supported by the Netherlands Science Foundation (NWO). H.R. was supported by the Chemical Sciences of the Netherlands Organization for Scientific Research (NWO-CW) and is recipient of the Otto-Hahn-Medaille of the Max-Planck-Gesellschaft. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
J Cell Sci. 2005 Mar 1; 118(Pt 5):843-6.
[J Cell Sci. 2005]Prog Nucleic Acid Res Mol Biol. 2002; 71():391-444.
[Prog Nucleic Acid Res Mol Biol. 2002]J Muscle Res Cell Motil. 2002; 23(7-8):729-36.
[J Muscle Res Cell Motil. 2002]EMBO J. 2001 Aug 15; 20(16):4490-9.
[EMBO J. 2001]BMC Genet. 2003 Jul 10; 4():12.
[BMC Genet. 2003]EMBO Rep. 2004 Jun; 5(6):602-6.
[EMBO Rep. 2004]Curr Biol. 1996 Jun 1; 6(6):719-29.
[Curr Biol. 1996]EMBO J. 2001 Aug 15; 20(16):4490-9.
[EMBO J. 2001]Genome Biol. 2005; 6(8):R68.
[Genome Biol. 2005]Proteomics. 2004 Sep; 4(9):2629-39.
[Proteomics. 2004]Biochemistry. 1990 Jun 26; 29(25):6058-65.
[Biochemistry. 1990]Genome Biol. 2005; 6(8):R68.
[Genome Biol. 2005]Curr Biol. 1996 Jun 1; 6(6):719-29.
[Curr Biol. 1996]EMBO J. 2001 Aug 15; 20(16):4490-9.
[EMBO J. 2001]Proteomics. 2004 Sep; 4(9):2629-39.
[Proteomics. 2004]Nucleic Acids Res. 2006 Jan 1; 34(Database issue):D423-7.
[Nucleic Acids Res. 2006]J Cell Biol. 1997 May 19; 137(4):891-8.
[J Cell Biol. 1997]J Cell Sci. 1998 Oct; 111 ( Pt 20)():3059-71.
[J Cell Sci. 1998]Mol Biol Cell. 2006 Oct; 17(10):4543-50.
[Mol Biol Cell. 2006]J Cell Biol. 2004 Nov 8; 167(3):505-18.
[J Cell Biol. 2004]EMBO Rep. 2004 Jun; 5(6):602-6.
[EMBO Rep. 2004]Cell. 2003 Feb 21; 112(4):549-60.
[Cell. 2003]Nature. 2003 Aug 7; 424(6949):694-8.
[Nature. 2003]Prog Nucleic Acid Res Mol Biol. 2002; 71():391-444.
[Prog Nucleic Acid Res Mol Biol. 2002]J Biol Chem. 1994 Sep 9; 269(36):22672-7.
[J Biol Chem. 1994]J Biol Chem. 2000 Jun 30; 275(26):20020-6.
[J Biol Chem. 2000]Oncogene. 2001 Apr 19; 20(17):2091-100.
[Oncogene. 2001]Nature. 1998 Jul 23; 394(6691):337-43.
[Nature. 1998]Biochem J. 1970 Sep; 119(2):171-4.
[Biochem J. 1970]EMBO Rep. 2004 Jun; 5(6):602-6.
[EMBO Rep. 2004]Biochemistry. 1998 May 19; 37(20):7420-30.
[Biochemistry. 1998]J Biol Chem. 2006 Aug 18; 281(33):23367-76.
[J Biol Chem. 2006]EMBO Rep. 2004 Jun; 5(6):602-6.
[EMBO Rep. 2004]Methods Enzymol. 1995; 255():95-109.
[Methods Enzymol. 1995]